Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

The activity of single-agent targeted molecular therapies in glioblastoma has been limited to date. The North American Brain Tumor Consortium examined the safety, pharmacokinetics, and efficacy of combination therapy with sorafenib, a small molecule inhibitor of Raf, vascular endothelial growth fact...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Lee, Eudocia Q., Kuhn, John, Lamborn, Kathleen R., Abrey, Lauren, DeAngelis, Lisa M., Lieberman, Frank, Robins, H. Ian, Chang, Susan M., Yung, W. K. Alfred, Drappatz, Jan, Mehta, Minesh P., Levin, Victor A., Aldape, Kenneth, Dancey, Janet E., Wright, John J., Prados, Michael D., Cloughesy, Timothy F., Gilbert, Mark R., Wen, Patrick Y.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2012
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3499017/
https://ncbi.nlm.nih.gov/pubmed/23099651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos264
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi